Successful desensitization under antihistamine suppression in a case with urticaria due to osimertinib
INTRODUCTION: Osimertinib is an approved therapy for patients with a Thr790met (T790M) mutation diagnosed with non-small cell lung cancer (NSCLC) that progresses during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. However, in 7-13% of patients, drug-related side effects lead to discontinuation of osimertinib treatment. In such cases, osimertinib desensitization is a treatment option that can be considered.
CASE REPORT: A 59-year-old female patient, who was followed up with the diagnosis of stage 4 NSCLC, was consulted to the allergy clinic because of urticaria. The patient developed urticaria plaques 20 h after the third dose of osimertinib tablet.
MANAGEMENT & OUTCOME: With the diagnosis of osimertinib-induced urticaria, desensitization was planned for the patient. Treatment was started with a dose of 0.1 mg/day osimertinib. The procedure was completed in approximately 50 days, and a dose of 80 mg/day was reached with antihistamine suppression.
DISCUSSION: Here, a successful osimertinib desensitization in a patient with a history of osimertinib-related type 1 allergic reaction is reported. Osimertinib desensitization is a treatment option that should be considered in cases where treatment has to be ceased due to drug-related side effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners - 28(2022), 6 vom: 21. Sept., Seite 1454-1457 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vural Solak, Gürgün Tuğçe [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.08.2022 Date Revised 15.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/10781552221075809 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335954073 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335954073 | ||
| 003 | DE-627 | ||
| 005 | 20231225231030.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/10781552221075809 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1119.xml |
| 035 | |a (DE-627)NLM335954073 | ||
| 035 | |a (NLM)35060790 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vural Solak, Gürgün Tuğçe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successful desensitization under antihistamine suppression in a case with urticaria due to osimertinib |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.08.2022 | ||
| 500 | |a Date Revised 15.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Osimertinib is an approved therapy for patients with a Thr790met (T790M) mutation diagnosed with non-small cell lung cancer (NSCLC) that progresses during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. However, in 7-13% of patients, drug-related side effects lead to discontinuation of osimertinib treatment. In such cases, osimertinib desensitization is a treatment option that can be considered | ||
| 520 | |a CASE REPORT: A 59-year-old female patient, who was followed up with the diagnosis of stage 4 NSCLC, was consulted to the allergy clinic because of urticaria. The patient developed urticaria plaques 20 h after the third dose of osimertinib tablet | ||
| 520 | |a MANAGEMENT & OUTCOME: With the diagnosis of osimertinib-induced urticaria, desensitization was planned for the patient. Treatment was started with a dose of 0.1 mg/day osimertinib. The procedure was completed in approximately 50 days, and a dose of 80 mg/day was reached with antihistamine suppression | ||
| 520 | |a DISCUSSION: Here, a successful osimertinib desensitization in a patient with a history of osimertinib-related type 1 allergic reaction is reported. Osimertinib desensitization is a treatment option that should be considered in cases where treatment has to be ceased due to drug-related side effects | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Osimertinib | |
| 650 | 4 | |a allergy | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a desensitization | |
| 650 | 4 | |a drug | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a urticaria | |
| 650 | 7 | |a Acrylamides |2 NLM | |
| 650 | 7 | |a Aniline Compounds |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Histamine Antagonists |2 NLM | |
| 650 | 7 | |a Histamine H1 Antagonists |2 NLM | |
| 650 | 7 | |a Indoles |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a osimertinib |2 NLM | |
| 650 | 7 | |a 3C06JJ0Z2O |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Aksu, Kurtuluş |e verfasserin |4 aut | |
| 700 | 1 | |a Topel, Musa |e verfasserin |4 aut | |
| 700 | 1 | |a Çuhadar Erçelebi, Dilek |e verfasserin |4 aut | |
| 700 | 1 | |a Yeşilkaya, Selma |e verfasserin |4 aut | |
| 700 | 1 | |a Demir, Şenay |e verfasserin |4 aut | |
| 700 | 1 | |a Köycü Buhari, Gözde |e verfasserin |4 aut | |
| 700 | 1 | |a Koca Kalkan, İlkay |e verfasserin |4 aut | |
| 700 | 1 | |a Ateş, Hale |e verfasserin |4 aut | |
| 700 | 1 | |a Nazik Bahçecioğlu, Sakine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners |d 1997 |g 28(2022), 6 vom: 21. Sept., Seite 1454-1457 |w (DE-627)NLM094530254 |x 1477-092X |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:6 |g day:21 |g month:09 |g pages:1454-1457 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/10781552221075809 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 6 |b 21 |c 09 |h 1454-1457 | ||